![\"Ivermection](\"https:\/\/www.tomgrimshaw.com\/tomsblog\/wp-content\/uploads\/2026\/05\/Ivermection_Anti-Cancer_Results.jpg\")
<\/p>\n<\/p>\n
BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal<\/p>\n
84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.<\/p>\n
Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research\u2014a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.<\/p>\n
The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.<\/p>\n
A diverse population of cancer patients (n=197) was prescribed compounded ivermectin\u2013mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.<\/p>\n
Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.<\/p>\n
At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)\u2014meaning more than four out of five patients reported either:
\nNo evidence of disease (32.8%)
\nTumor regression (15.6%)
\nor Cancer stabilization (36.1%)<\/p>\n
Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.<\/p>\n
Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.<\/p>\n
This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel\u2014uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.<\/p>\n
With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required. <\/p>\n
In the meantime, many cancer patients are exercising their right to try.<\/p>\n